Drug news
EU approval for Seebri Breezhaler (Novartis) for COPD
Novartis announced that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). This follows the September 28 approval of once-daily Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg in Japan.